Effects of Exercise in Patients With Repaired Coarctation of the Aorta (KOREKT)
Effects of Exercise on Select Indicators of Cardiovascular Health in Patients With Repaired Coarctation of the Aorta
This interventional study will investigate the effects of high-intensity interval training (HIIT) in adults with repaired coarctation of the aorta. Participants will be randomised into three groups: HIIT performed at home, HIIT performed in a supervised outpatient setting, or a control group receiving usual care. The two HIIT protocols will be identical in intensity and progression, individually prescribed for each patient.
The study will evaluate the effects of HIIT on exercise capacity, health-related quality of life, blood pressure response to exercise, and other select measures of cardiovascular health, including vascular stiffness and endothelial function. In addition, the study will examine the acute effects of a single exercise session on arterial stiffness.
Aperçu de l'étude
Statut
Les conditions
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
-
Ljubljana, Slovénie, 1000
- University Medical Centre Ljubljana
-
Maribor, Slovénie, 2000
- University Medical Centre Maribor
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- surgically repaired coarctation of the aorta,
- age at least 18 years, and
- signed informed consent form.
Exclusion Criteria:
- residual aortic stenosis (gradient across the narrowing >20 mmHg),
- presence of ascending aortic aneurysm,
- recent major cardiovascular event or other event requiring hospitalization (event less than 2 months before inclusion),
- unstable rhythm disturbances,
- unstable or low-threshold angina pectoris,
- NYHA class III or IV heart failure, and
- pregnancy.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Outpatient HIIT
Anticipated number of patients: 15. Participants will complete a structured high-intensity interval training (HIIT) programme performed in an outpatient setting. Intensity and progression are identical to the home-based HIIT arm. |
A structured exercise programme performed under direct supervision in an outpatient/clinical setting on a stationary bicycle or treadmill, consisting of 36 one-hour sessions over 2-4 months (approximately 2-3 sessions per week). Each session will comprise 8 five-minute intervals, each consisting of 2 minutes at 85-95% of the heart rate reached at VO2peak, followed by 3 minutes of active recovery. The interval block will be preceded by a 5-minute active warm-up and followed by a 5-minute active cool-down. Interval intensity will be individually determined for each patient. |
|
Expérimental: Home-based HIIT
Anticipated number of patients: 15. Participants will complete a structured high-intensity interval training (HIIT) programme performed independently at home. Intensity and progression are identical to the outpatient HIIT arm. |
A structured exercise programme performed independently at home, consisting of 36 one-hour sessions over 2-4 months (approximately 2-3 sessions per week). Each session will comprise 8 five-minute intervals, each consisting of 2 minutes at 85-95% of the heart rate reached at VO2peak, followed by 3 minutes of active recovery. The interval block will be preceded by a 5-minute active warm-up and followed by a 5-minute active cool-down. Interval intensity will be individually determined for each patient. |
|
Aucune intervention: Control (usual care)
Anticipated number of patients: 15. Participants will receive usual care, consisting of general counselling on physical activity performed at home, without a structured or supervised exercise training programme. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
VO2peak on cardiopulmonary exercise testing (CPET)
Délai: At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
Hypothesis: The outpatient high-intensity interval training (HIIT) programme improves aerobic capacity (measured by VO2peak) more than a home-based HIIT program or usual care.
|
At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
|
Health-related quality of life
Délai: At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
Hypothesis: The outpatient high-intensity interval training (HIIT) programme improves health-related quality of life, assessed using the standardised SF-36 and EQ-5D questionnaires, more than a home-based HIIT programme or usual care.
|
At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
|
Ratio of peak systolic blood pressure to peak workload (mmHg/W) on CPET
Délai: At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
Hypothesis: The outpatient high-intensity interval training (HIIT) programme reduces the ratio between peak systolic blood pressure and peak workload achieved during exercise testing more than a home-based HIIT programme or usual care.
|
At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Mean 24-hour systolic blood pressure
Délai: At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
Assessment of average systolic pressure during sleep and wakefulness, measured using 24-hour ambulatory blood pressure monitoring.
|
At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
|
Echocardiographic parameters
Délai: At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
Assessment of standard echocardiographic measures of cardiac structure and function, including left ventricular global longitudinal strain (GLS).
|
At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
|
Endothelial function of the right radial artery (flow-mediated dilation, FMD)
Délai: At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
Ultrasound assessment of endothelial function of the right radial artery, measured by flow-mediated dilation (FMD).
|
At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
|
Heart rate variability
Délai: At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
Assessment of heart rate variability using high-resolution electrocardiography.
|
At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
|
Biomarkers associated with vascular stiffness and atherosclerosis
Délai: At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
Assessment of circulating biomarkers associated with vascular stiffness and atherosclerosis, including atrial natriuretic peptide (ANP), growth/differentiation factor 15 (GDF-15), matrix metalloproteinase 1 (MMP-1), interleukin-33 receptor (IL-33/ST2), brain-derived neurotrophic factor (BDNF), galectin-3, myeloperoxidase, and tissue inhibitor of metalloproteinase 1 (TIMP-1).
|
At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
|
Self-reported physical activity
Délai: At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
Self-reported physical activity level, assessed using the standardised International Physical Activity Questionnaire (IPAQ).
|
At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Body composition
Délai: At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
Assessment of body composition using bioelectrical impedance analysis.
|
At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
|
Standard laboratory panel
Délai: At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
Assessment of standard laboratory parameters: electrolytes, renal function markers, liver function tests.
|
At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
|
NT-proBNP
Délai: At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
Assessment of NT-proBNP
|
At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
|
Extended lipid panel
Délai: At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
Assessment extended lipid panel, including Lp(a).
|
At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
|
Thyroid hormone level
Délai: At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
Assessment of thyroid hormones.
|
At baseline and on follow-up assessment, with follow-up occurring within 3-12 months after baseline.
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 0120-101/2025-2711-4
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- CIF
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .